Blue Trust Inc. Acquires 1,024 Shares of Moderna, Inc. (NASDAQ:MRNA)

Blue Trust Inc. increased its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 140.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,755 shares of the company’s stock after purchasing an additional 1,024 shares during the period. Blue Trust Inc.’s holdings in Moderna were worth $73,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Intrinsic Value Partners LLC lifted its holdings in shares of Moderna by 91.1% during the 3rd quarter. Intrinsic Value Partners LLC now owns 51,392 shares of the company’s stock valued at $3,435,000 after purchasing an additional 24,505 shares in the last quarter. Banco Santander S.A. acquired a new stake in Moderna in the 3rd quarter valued at approximately $3,550,000. John G Ullman & Associates Inc. raised its position in Moderna by 341.3% in the 3rd quarter. John G Ullman & Associates Inc. now owns 49,650 shares of the company’s stock valued at $3,318,000 after buying an additional 38,400 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. raised its position in Moderna by 11.6% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,614,313 shares of the company’s stock valued at $107,885,000 after buying an additional 167,596 shares during the last quarter. Finally, abrdn plc raised its position in Moderna by 28.1% in the 4th quarter. abrdn plc now owns 315,912 shares of the company’s stock valued at $12,842,000 after buying an additional 69,360 shares during the last quarter. Institutional investors own 75.33% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on MRNA shares. Hsbc Global Res raised Moderna from a “hold” rating to a “strong-buy” rating in a research report on Monday, November 18th. The Goldman Sachs Group lowered Moderna from a “buy” rating to a “neutral” rating and dropped their target price for the company from $99.00 to $51.00 in a research report on Wednesday, January 29th. HSBC raised Moderna from a “hold” rating to a “buy” rating and set a $58.00 target price on the stock in a research report on Monday, November 18th. UBS Group lowered their price target on Moderna from $96.00 to $78.00 and set a “buy” rating on the stock in a research report on Wednesday, February 19th. Finally, Morgan Stanley lowered their price target on Moderna from $70.00 to $38.00 and set an “equal weight” rating on the stock in a research report on Wednesday, January 15th. Four investment analysts have rated the stock with a sell rating, fifteen have given a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Moderna has a consensus rating of “Hold” and a consensus price target of $60.63.

Insider Transactions at Moderna

In related news, insider Shannon Thyme Klinger sold 1,418 shares of the business’s stock in a transaction on Friday, November 29th. The stock was sold at an average price of $42.79, for a total value of $60,676.22. Following the completion of the sale, the insider now directly owns 19,717 shares in the company, valued at $843,690.43. The trade was a 6.71 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In the last three months, insiders sold 2,664 shares of company stock worth $115,210. 15.70% of the stock is owned by company insiders.

Moderna Trading Up 5.3 %

Shares of NASDAQ MRNA opened at $35.53 on Monday. Moderna, Inc. has a 12 month low of $29.25 and a 12 month high of $170.47. The stock has a 50 day moving average of $38.04 and a 200-day moving average of $52.46. The company has a market capitalization of $13.67 billion, a P/E ratio of -3.83 and a beta of 1.59.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.